First-in-Human trial targets Hard-to-Treat cancers with unique genetic flaw

NCT ID NCT06188702

Recruiting now Disease control Sponsor: Servier Bio-Innovation LLC Source: ClinicalTrials.gov ↗

Summary

This study is testing a new oral drug called S095035, both by itself and combined with another drug, for adults with advanced or metastatic solid tumors that have a specific genetic change (homozygous MTAP deletion). The main goals are to find a safe dose and see if the treatment can shrink tumors in patients who have run out of standard treatment options. It is an early-phase trial enrolling about 342 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

A.O.U. Seconda Università Degli Studi Di Napoli
NOT_YET_RECRUITING

Naples, 80131, Italy
Aichi Cancer Center
RECRUITING

Aichi, 4648681, Japan
Centre Georges-François Leclerc
RECRUITING

Dijon, 21079, France
Charite Universitatsmedizin
NOT_YET_RECRUITING

Berlin, 13353, Germany
Community Health Network
RECRUITING

Indianapolis, Indiana, 46250, United States
Dana Farber Cancer Institue
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Duke University School of Medicine
NOT_YET_RECRUITING

Durham, North Carolina, 27710, United States
Hospital Universitario Fundación Jiménez Díaz
RECRUITING

Madrid, 28040, Spain
Hospital Vall D'Hebron
NOT_YET_RECRUITING

Barcelona, 8035, Spain
Hôpital de la Timone (Marseille)
RECRUITING

Marseille, 13385, France
Institut Bergonié
NOT_YET_RECRUITING

Bordeaux, 33076, France
Institut Gustave Roussy
RECRUITING

Paris, 94805, France
Instituto Clinico Humanitas Irccs
RECRUITING

Rozzano, 20098, Italy
Ist. Nazionale Tumori Irccs Fondazione G Pascale
RECRUITING

Naples, 80131, Italy
Istituto Europeo Di Oncologia
NOT_YET_RECRUITING

Milan, 20141, Italy
Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute
TERMINATED

Lake Mary, Florida, 32746, United States
Med Fakultaet Heidelberg
NOT_YET_RECRUITING

Heidelberg, 69120, Germany
NEXT Oncology
RECRUITING

Austin, Texas, 78758, United States
National Hospital Organization Shikoku Cancer Center
RECRUITING

Ehime, 7910280, Japan
Next Oncology-Hospital Quironsalud Barcelona
RECRUITING

Barcelona, 8023, Spain
Odense Universitets Hospital
NOT_YET_RECRUITING

Odense, 5000, Denmark
Policlinico G.B. Rossi A.O.U.I. Di Verona
RECRUITING

Verona, 37134, Italy
Royal Hobart Hospital
SUSPENDED

Hobart, 7000, Australia
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Scientia Clinical Research
RECRUITING

Randwick, New South Wales, 2031, Australia
Start Madrid Group - Hm Ciocc
RECRUITING

Madrid, 28050, Spain
Taylor Cancer Research Center
RECRUITING

Maumee, Ohio, 43537, United States
The Alfred
RECRUITING

Prahran, Victoria, 3004, Australia
The Cancer Institute Hospital of JFCR
RECRUITING

Tokyo, 1358550, Japan
Townsville University Hospital
RECRUITING

Douglas, 4812, Australia
University Hospital Rigshospitalet
NOT_YET_RECRUITING

Copenhagen, 2100, Denmark
University of California Los Angeles
NOT_YET_RECRUITING

Los Angeles, California, 90095, United States
University of California, San Francisco (Ucsf) School of Medicine
NOT_YET_RECRUITING

San Francisco, California, 94143, United States
Universitätsklinikum Düsseldorf
NOT_YET_RECRUITING

Düsseldorf, 40225, Germany
Universitätsklinikum Ulm
RECRUITING

Ulm, 89081, Germany

Conditions

Explore the condition pages connected to this study.

MTAP-DELETED SOLID TUMORS